Emergent BioSolutions Inc
EBS7.940USD
+0.150+1.93%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
426.38MMarket Cap
3.06P/E TTM
More Details of Emergent BioSolutions Inc Company
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
Company Info
Ticker SymbolEBS
Company nameEmergent BioSolutions Inc
IPO dateNov 15, 2006
CEOMr. Joseph C. (Joe) Papa
Number of employees900
Security typeOrdinary Share
Fiscal year-endNov 15
Address300 Professional Dr
CityGAITHERSBURG
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code20879
Phone12406313200
Websitehttps://emergentbiosolutions.com/
Ticker SymbolEBS
IPO dateNov 15, 2006
CEOMr. Joseph C. (Joe) Papa
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
342.50K
+21.24%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
201.49K
-1.34%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
121.47K
-1.02%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
118.86K
+40.74%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
103.49K
+49.80%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
91.98K
+211.99%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
85.27K
+67.63%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
68.39K
+1061.66%
Mr. Marvin L. White
Mr. Marvin L. White
Independent Director
Independent Director
68.25K
+101.64%
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
66.14K
-10.60%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
342.50K
+21.24%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
201.49K
-1.34%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
121.47K
-1.02%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
118.86K
+40.74%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
103.49K
+49.80%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
91.98K
+211.99%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
MCM Product sales
156.60M
70.48%
Commercial Product sales
45.30M
20.39%
Contracts and grants
20.30M
9.14%
By RegionUSD
Name
Revenue
Proportion
Non-U.S Government
143.40M
64.54%
U.S.Government
78.80M
35.46%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
MCM Product sales
156.60M
70.48%
Commercial Product sales
45.30M
20.39%
Contracts and grants
20.30M
9.14%
Shareholding Stats
Updated: Wed, Aug 20
Updated: Wed, Aug 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.18%
The Vanguard Group, Inc.
6.72%
American Century Investment Management, Inc.
4.30%
Dimensional Fund Advisors, L.P.
3.47%
State Street Global Advisors (US)
3.26%
Other
75.08%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.18%
The Vanguard Group, Inc.
6.72%
American Century Investment Management, Inc.
4.30%
Dimensional Fund Advisors, L.P.
3.47%
State Street Global Advisors (US)
3.26%
Other
75.08%
Shareholder Types
Shareholders
Proportion
Investment Advisor
32.04%
Investment Advisor/Hedge Fund
23.85%
Hedge Fund
9.40%
Individual Investor
3.07%
Research Firm
2.91%
Bank and Trust
1.00%
Pension Fund
0.77%
Sovereign Wealth Fund
0.18%
Venture Capital
0.05%
Other
26.72%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
444
39.60M
73.05%
-8.24M
2025Q1
472
38.22M
70.45%
-8.61M
2024Q4
475
36.31M
66.90%
-8.91M
2024Q3
485
33.46M
61.86%
-11.26M
2024Q2
503
32.16M
60.76%
-21.31M
2024Q1
512
37.52M
71.59%
-17.68M
2023Q4
531
43.49M
83.79%
-11.00M
2023Q3
581
43.88M
84.66%
-15.71M
2023Q2
596
48.59M
93.79%
-8.52M
2023Q1
682
47.08M
93.36%
-12.05M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
1.58M
2.92%
-61.06K
-3.71%
Mar 31, 2025
The Vanguard Group, Inc.
3.21M
5.92%
+13.30K
+0.42%
Mar 31, 2025
American Century Investment Management, Inc.
2.30M
4.23%
+159.91K
+7.48%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.60M
2.94%
+492.58K
+44.62%
Mar 31, 2025
State Street Global Advisors (US)
1.71M
3.15%
-253.01K
-12.88%
Mar 31, 2025
Oak Hill Advisors, L.P.
1.11M
2.05%
--
--
Mar 31, 2025
Palisade Capital Management, LLC
1.14M
2.1%
+202.86K
+21.61%
Mar 31, 2025
Marshall Wace LLP
1.16M
2.13%
-170.78K
-12.85%
Mar 31, 2025
View more
Related ETFs
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Name
Proportion
Federated Hermes MDT Small Cap Core ETF
0.17%
Harbor Human Capital Factor US Small Cap ETF
0.15%
Invesco RAFI US 1500 Small-Mid ETF
0.13%
SPDR S&P Biotech ETF
0.11%
Pacer US Small Cap Cash Cows ETF
0.07%
iShares Micro-Cap ETF
0.07%
Direxion Daily S&P Biotech Bull 3X Shares
0.07%
Avantis US Small Cap Value ETF
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
Avantis US Small Cap Equity ETF
0.04%
View more
Federated Hermes MDT Small Cap Core ETF
Proportion0.17%
Harbor Human Capital Factor US Small Cap ETF
Proportion0.15%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.13%
SPDR S&P Biotech ETF
Proportion0.11%
Pacer US Small Cap Cash Cows ETF
Proportion0.07%
iShares Micro-Cap ETF
Proportion0.07%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.07%
Avantis US Small Cap Value ETF
Proportion0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.05%
Avantis US Small Cap Equity ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
